Patents by Inventor Patrik KEHLER

Patrik KEHLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES AGAINST LEWIS Y
    Publication number: 20230235076
    Abstract: The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: June 29, 2021
    Publication date: July 27, 2023
    Inventors: Antje DANIELCZYK, Johanna GELLERT, Anke FLECHNER, Patrik KEHLER
  • Prame TCR Receptors And Uses Thereof
    Publication number: 20220401484
    Abstract: The present invention relates to a T cell receptor (TCR) capable of binding to a PRAME peptide having the amino acid sequence SLLQHLIGL (SEQ ID NO: 1) or a portion thereof, or its HLA-A2 bound form. Also encompassed in the present invention is a nucleic acid encoding a TCR, a vector comprising the nucleic acid, and a host cell comprising the TCR, the nucleic acid sequence, or said vector. Comprised is further, a method for obtaining a TCR described herein, a pharmaceutical or diagnostic composition, and a method of detecting the presence of a cancer in a subject in vitro.
    Type: Application
    Filed: November 18, 2020
    Publication date: December 22, 2022
    Inventors: Manon Weis, Patrik Kehler, Maria Gerget, Christian Krendl, Susanne Wilde
  • Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
    Publication number: 20210107961
    Abstract: The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Johanna GELLERT, Patrik KEHLER, Anika JÄKEL, Laura DIX, Antje DANIELCZYK, Steffen GOLETZ
  • PD-L1 AND TA-MUC1 ANTIBODIES
    Publication number: 20200148785
    Abstract: The present invention relates to an antibody which effects enhanced T cell activation in comparison to a reference antibody being glycosylated including more than 80% core-fucosylation and wherein T cell activation is effected by an antibody characterized by enhanced binding to Fc#RIIIa. Said antibody is glycosylated, but essentially lacks core-fucosylation.
    Type: Application
    Filed: March 28, 2018
    Publication date: May 14, 2020
    Inventors: Patrik Kehler, Steffen Goletz, Antje Danielczyk, Johanna Ruehmann, Christoph Goletz
  • MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
    Publication number: 20200131275
    Abstract: The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 30, 2020
    Inventors: Steffen GOLETZ, Patrik KEHLER, Johanna GELLERT, Antje DANIELCZYK, Anika JÄKEL